So far, several markers associated with the positive response to PD‐1/PD‐L1 mAbs have been proposed, including, tumour infiltrated lymphocytes (TIL), tumour mutation burden (TMB), microsatellite instability, and PD‐L1 expression in tumors.4 Here, CD274 is linked to neoplasm.